Background
==========

According to the Organ Procurement and Transplantation Network (OPTN)/Scientific Registry of Transplant Recipients (SRTR) 2017 Annual Data Report, there were 92,685 patients on the waitlist for a kidney transplant, with an increasing number of patients waiting 5 years or longer to be transplanted \[[@b1-anntransplant-25-e924061]\]. As such, it is important to identify those patients who are at higher risk of graft loss prior to listing in order to reduce wait times for those more likely to have long-term graft survival. Identifying patients at risk for post-transplant noncompliance could theoretically increase patient years gained by kidney transplantation, as well as lead to huge savings in healthcare costs \[[@b2-anntransplant-25-e924061]--[@b9-anntransplant-25-e924061]\].

Previous studies have found significant correlation between post-transplant noncompliance and graft rejection when using pre-transplant measures such as compliance with dialysis visits, drug screening, and documented history of medical noncompliance \[[@b10-anntransplant-25-e924061]\]. Since about 40% of ESRD patients are diabetic, HbA~1c~ could be a useful and objective tool for predicting post-transplant compliance in this group. Previous studies have examined the correlation between HbA~1c~ and graft outcomes, finding that post-transplant glycemic control is more important than pre-transplant glycemic control for long-term graft outcomes, but that acute rejection was not associated with either \[[@b11-anntransplant-25-e924061]\]. Several studies \[[@b12-anntransplant-25-e924061]--[@b14-anntransplant-25-e924061]\] have also looked at the relationship between HbA~1c~ level and compliance with anti-diabetic medication in diabetic patients, but none has assessed whether this data translates to using pre-transplant HbA~1c~ to predict compliance in the post-transplant period. Given that many institutions, including our own, still rely on pre-transplant HbA~1c~ to determine patient appropriateness for listing, despite the paucity of relevant literature, we sought to further examine if, beyond graft outcomes, HbA~1c~ is correlated with patient compliance following kidney transplant.

Compliance is the extent to which patient behavior coincides with health advice given \[[@b10-anntransplant-25-e924061],[@b15-anntransplant-25-e924061],[@b16-anntransplant-25-e924061]\]. The opposite -- noncompliance -- is an important cause of graft dysfunction in transplant patients secondary to rejection episodes. The prevalence of noncompliance is widely variable. Reviewed cohort and cross-sectional studies found that 15--22% of post-transplant patients are noncompliant \[[@b17-anntransplant-25-e924061]\]. In a large meta-analysis that included over 29,000 transplant patients, a non-adherence rate of about 33% per-patient-year was noted in North America \[[@b18-anntransplant-25-e924061]\]. Noncompliance is significant in that it leads to recurrent hospitalization, decreased graft function, and eventually to graft loss necessitating return to dialysis; therefore, identifying potential non-compliers is important \[[@b2-anntransplant-25-e924061]--[@b9-anntransplant-25-e924061]\].

The pre-transplant evaluation process is widely variable across United States transplant centers. In our program, several measures are used pre-transplant to predict a patient's post-transplant compliance, including compliance with dialysis visits, compliance with office visits, and HbA~1c~ level in diabetic patients. A HbA~1c~ level of \>10% is used at our center, based mainly on historical institutional practice, as a flag that the patient may be at high risk for post-transplant noncompliance and that more comprehensive psychosocial screening and teaching is needed prior to listing for transplant.

This study aimed to evaluate the association between pre-transplant HbA~1c~ level and post-transplant compliance. We hypothesized that assessment of pre-transplant diabetic control, using HbA~1c~ level, will lead to identifying those patients with high risk of post-transplant noncompliance.

Material and Methods
====================

After obtaining Institutional Review Board approval, data of diabetic kidney transplant recipients between July 2008 and June 2012 at our institution were retrieved from a prospectively maintained database. Additional information such as patient demographics, type of diabetes, pre-transplant HbA~1c~, graft outcomes, immunosuppressant levels, and documented noncompliance were obtained by retrospective electronic chart review. Factors that may affect graft and patient outcomes, such as cold ischemia time, warm ischemia time, donor age, graft type, and panel reactive antibody (PRA), were also reviewed. Diabetic patients that received a kidney transplant alone were included in the statistical analysis. The follow-up period ranged from 1 to 5 years post-transplant, with a mean follow-up of 3.5 years.

The HbA~1c~ cutoff used in this study was chosen based upon previously published literature in the non-transplant diabetic population which examined the correlation between HbA~1c~ and compliance and found that HbA~1c~ level higher than 7.7% is associated with poor compliance with medications \[[@b12-anntransplant-25-e924061]\]. Based on this literature, a value of 7.7% was used as the cutoff to define preoperative compliance, with values of less than or equal to 7.7% defined as compliant and values of greater than 7.7% defined as noncompliant.

The primary outcome of interest was post-transplant compliance. Surrogate outcome measures for compliance included graft failure, graft rejection episodes, medical noncompliance, and unexplained low immunosuppressant blood levels (less than 4 ng/ml for Tacrolimus or Rapamycin after 1 month from the date of transplant procedure). At the institution where the study was conducted, the transplant team aims to achieve target immunosuppression levels by 4 weeks post-transplant; therefore, if immunosuppression levels are sub-therapeutic at that time without a clear explanation, a patient was suspected to be noncompliant with medication. Rejection episodes were confirmed by histopathology reports of kidney biopsy samples.

A summary of the baseline recipient, donor, and operative characteristics is presented in terms of mean and standard deviation for continuous variables and frequencies and percentages for dichotomous variables. Group differences in continuous variables were tested with *t* tests in data expected to be normally distributed and with Mann-Whitney-Wilcoxon test for data expected to be non-normally distributed. The relationships among categorical variables were examined with the chi-square test. Regression analyses were used to assess the predictive value of HbA~1c~ on outcome measures. The analysis was conducted using SPSS^®^ (version 18).

Results
=======

The total number of patients who were diabetic and had a kidney transplant alone in the study period was 165. Baseline patient demographics are found in [Table 1](#t1-anntransplant-25-e924061){ref-type="table"}. Additional measures included were average cold ischemia time of 21.6 h and the average anastomotic time of 48.8 min. The overall number of patients who had graft failure was 30 (18.0%) and the number of patients who had at least 1 rejection episode was 22 (13.0%). Baseline characteristics, with HbA~1c~ level of 7.7% as a cutoff point, are shown in [Table 2](#t2-anntransplant-25-e924061){ref-type="table"}. There were no significant differences in the donor, recipient, and operative characteristics between the 2 groups.

There was no statistically significant difference in the outcomes of interest, including failed graft (22.2% and 13.3%, p=0.2), rejection episodes (14.8% and 6.7%, p=0.3), low immunosuppressant level (46.7% and 60.0%, p=0.3), and documented noncompliance (25.9% and 16.7%, p=0.4) when comparing recipients with HbA~1c~ less than or equal to and greater than 7.7%, respectively (see [Table 3](#t3-anntransplant-25-e924061){ref-type="table"}). This was true whether chi-square tests or logistic regression analyses were used.

Additionally, we examined the mean HbA~1c~ levels for patients who had graft failure, rejection, or documented noncompliance to determine if there was a more sensitive HbA~1c~ cutoff which could be used. In doing this, we found there were no significant differences between mean HbA~1c~ levels for patients who had graft failure compared to those with functioning grafts (6.6% and 6.5%, respectively, *p*=0.4) and for patients who had rejection episodes and those who did not (6.6% and 6.5%, respectively, *p*=0.8). There was also no significant difference between HbA~1c~ level of patients who were documented to be noncompliant with their medications compared with those who had no documentation of noncompliance (6.6% and 6.4%, respectively, *p*=0.7); see [Table 4](#t4-anntransplant-25-e924061){ref-type="table"}.

Discussion
==========

ESRD is a major health issue, costing the United States Medicare program an estimated \$35 billion in 2016 \[[@b19-anntransplant-25-e924061]\]. In the United States, the incidence and prevalence of ESRD continues to rise. According to United States Renal Data System (USRDS), on December 31, 2016, there were 726,331 prevalent cases of ESRD in the United States, with the number of prevalent ESRD cases rising by approximately 20,000 per year \[[@b19-anntransplant-25-e924061]\]. The main treatment option for ESRD is kidney transplant. However, with 92,685 patients on the waitlist for kidney transplant, there is a strong need to determine which patients will benefit from transplant and which patients are at high risk for organ rejection or failure \[[@b1-anntransplant-25-e924061]\]. Currently, this is done through widely variable preoperative evaluation and screening practices, including assessment of compliance with dialysis visits, drug screening, socioeconomic status, family support, and documented history of medical noncompliance, in order to determine if a patient will be compliant in the post-transplant period \[[@b10-anntransplant-25-e924061]\]. Pre-transplant HbA~1c~ levels are also used in the assessment of patient compliance prior to transplant listing, despite a paucity of data to support a standard cutoff value or its relationship to kidney transplant outcomes.

In this retrospective study, HbA~1c~ was tested to determine if it is a valid predictor of compliance with non-diabetic post-transplant medications in diabetic ESRD patients. Based on a previous study that showed non-ESRD diabetic patients with HbA~1c~ above 7.7% were at higher risk of noncompliance with diabetic medications compared to those with HbA~1c~ below this value, 7.7% was chosen as a cutoff for this study \[[@b12-anntransplant-25-e924061]\]. Graft outcomes, rejection episodes, documented noncompliance, and low therapeutic medication levels were used to assess patient compliance and were compared with the preoperative HbA~1c~ level. This study did not show any significant difference between those with HbA~1c~ level above or below 7.7% in the outcome variables of interest. Interestingly, the mean HbA~1c~ (6.5%) for patients that received a kidney transplant at our institution was less than the mean HbA~1c~ (7.2%) for adult diabetic patients in the United States, using the Center for Disease Control data for the same period (see [Table 5](#t5-anntransplant-25-e924061){ref-type="table"}). The difference in the mean HbA~1c~ levels could be a result of the improved glycemic control seen in ESRD due to decreased insulin excretion and decreased insulin requirements compared with the general diabetic population \[[@b20-anntransplant-25-e924061],[@b21-anntransplant-25-e924061],[@b22-anntransplant-25-e924061]\]. Additionally, several factors have been shown to cause variations in measured HbA~1c~ levels in patients with ESRD, including anemia, blood transfusion, race, age, hemoglobinopathies, hemodialysis, and the administration of erythropoietin \[[@b23-anntransplant-25-e924061],[@b24-anntransplant-25-e924061]\]; therefore, pre-transplant HbA1c level should be interpreted with caution. Alternatively, glycated albumin is not significantly affected by these factors and could be a better marker of glycemic control in this patient population \[[@b25-anntransplant-25-e924061]\]; however, the use of alternative biomarkers such as fructosamine and glycated albumin outside the research setting has not been sufficiently validated and may be unreliable if there is hypoalbuminemia. For these reasons, the use of correction factor for HbA~1c~ measurement in patients on dialysis has been proposed \[[@b26-anntransplant-25-e924061]\] and may be better.

Looking specifically at the patients with HbA~1c~ levels above 10%, the cutoff value typically used by our program for transplant listing, we observed 1 graft loss, giving a 33.3% overall graft failure for this group. The graft loss was preceded by 2 rejection episodes (acute antibody mediated rejection and acute cellular rejection), and later followed by death from a pulmonary embolism. Another important observation is that all patients with HbA~1c~ levels above 10% had unexplained low immunosuppressant levels. Although this is a very small group, the data points towards a trend with poor post-transplant outcomes and compliance compared to those with HbA~1c~ below 10%. Additional research in centers that do not use HbA~1c~ of 10% as a cutoff for listing patients may give more information.

There are several factors that may play a role in the lack of correlation observed between pre-transplant glycemic control and post-transplant compliance. Glycemic control is influenced by several factors beyond medication compliance which may be more difficult for a patient to control, including diet and exercise. Additionally, appropriate glycemic control often requires finger-stick glucose monitoring, medication calculations, and insulin injections multiple times per day, whereas post-transplant medication compliance usually only requires a patient to take the appropriate immunosuppressant and prophylactic medications by mouth once or twice per day. The variability of pre-transplant HbA~1c~ and the many factors that may affect it further support the findings from this study that patients should not be excluded from listing based on pre-transplant HbA~1c~ levels alone.

Limitations of this study include its retrospective design and selection bias for patients who are more likely to be compliant by our current institutional listing criteria. As a result, the number of patients with elevated pre-transplant HbA~1c~ level was relatively small. Another limitation is that HbA~1c~ levels may not be as meaningful in the ESRD population as compared to the general diabetic population \[[@b27-anntransplant-25-e924061]--[@b29-anntransplant-25-e924061]\]. Future studies evaluating the association between glycated albumin or corrected HbA~1c~ on post-transplant compliance may offer further information. Additionally, it is not part of our institutional protocol to perform routine biopsies after transplant; however, in an institution where this is performed, it may give more information on the correlation between pre-transplant glycemic control and post-transplant graft outcomes. Furthermore, it is possible that a longer follow-up period would affect the outcomes of graft rejection or failure. The value of this study is that it is the first study to look at the relationship between pre-transplant HbA~1c~ and post-transplant compliance, and it demonstrates that pre-transplant HbA~1c~ level is not predictive of post-transplant compliance and outcomes; this may limit the unnecessary exclusion of diabetic patients struggling with glycemic control from listing for transplant.

Conclusions
===========

This retrospective study found no correlation between elevated pre-transplant HbA~1c~ levels, defined as HbA~1c~ \>7.7%, and post-transplant medication compliance in diabetic ESRD patients undergoing renal transplant. The findings from this study may better inform transplant programs when deciding on selection criteria for transplant listing. Further prospective studies are needed to better evaluate the role of HbA~1c~ in transplant outcomes.
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###### 

Baseline recipient characteristics.

                                  N     Percent (%)   Mean
  ------------------------------- ----- ------------- ------
  Total                           165                 
  Gender                                              
   Male                           107   65.0          
   Female                         58    35.0          
  Age (17--81 years)                                  57.6
  Race                                                
   White                          41    24.8          
   Black                          63    38.2          
   Hispanic                       49    29.7          
   Other                          12    7.3           
  BMI (kg/m^2^)                                       29.5
  HbA~1c~ (%)                                         6.5
  Time on hemodialysis (months)                       45.0

###### 

Baseline recipient, donor, and operative characteristics by HbA~1c~ level.

                               HbA~1c~ ≤7.7% (135 patients)                  HbA~1c~ \>7.7% (30 patients)                   *p*-Value
  ---------------------------- --------------------------------------------- ---------------------------------------------- -----------
  Recipient age (years)        57.9 (10.2)                                   56.1 (9.6)                                     0.40
  BMI (kg/m^2^)                29 (5.2)                                      30.5 (5.2)                                     0.13
  Time on dialysis (months)    47 (39.5)                                     35 (29.0)                                      0.25
  Length of stay (days)        9.3 (14) \[[@b6-anntransplant-25-e924061]\]   7.2 (2.7) \[[@b6-anntransplant-25-e924061]\]   0.80
  Cold ischemia time (hours)   22 (9.8)                                      20 (10.6)                                      0.40
  Anastomotic time (minutes)   49 (15.2)                                     47 (11.5)                                      0.70
  PRA                          11.8 (23.8)                                   17.6 (33.4)                                    0.90
  Follow-up (months)           39.2 (14.7)                                   42 (16.4)                                      0.21
  Donor age (years)            42 (17)                                       44 (15)                                        0.50
  Re-transplant                                                                                                             0.50
   Yes                         13 (10%)                                      3 (10%)                                        
   No                          122 (90%)                                     27 (90%)                                       
  Gender                                                                                                                    0.80
   Female                      49 (36%)                                      9 (30%)                                        
   Male                        86 (64%)                                      21 (70%)                                       
  Race                                                                                                                      0.70
   Black                       52 (39%)                                      11 (36.7%)                                     
   Hispanic                    38 (28%)                                      11 (36.7%)                                     
   White                       34 (25%)                                      7 (23.3%)                                      
   Other                       11 (8%)                                       1 (3.3%)                                       
  Type of diabetes                                                                                                          0.05
   Type I                      4 (3%)                                        6 (20%)                                        
   Type II                     111 (82%)                                     22 (73.3%)                                     
   Unclassified                20 (15%)                                      2 (6.7%)                                       
  Diabetic medications                                                                                                      0.40
   Insulin                     92 (68%)                                      23 (77%)                                       
   OHA                         21 (15%)                                      4 (13%)                                        
   Both                        18 (13%)                                      3 (10%)                                        
  Type of graft                                                                                                             0.26
   SCD                         93 (69%)                                      16 (53%)                                       
   ECD                         27 (20%)                                      9 (30%)                                        
   DCD                         15 (11%)                                      5 (17%)                                        
  Donor type                                                                                                                0.18
   Deceased donors             70 (52%)                                      17 (57%)                                       
   Living donors               65 (48%)                                      13 (43%)                                       

Data presented as mean (standard deviation) \[median\] or count (percentage). PRA -- Panel Reactive Antibody; OHA -- Oral Hypoglycemic Agent; SCD -- Standard Criteria Donor; ECD -- Extended Criteria Donor; DCD -- Donation after Cardiac Death.

###### 

Outcome measures by HbA~1c~ Level.

                                HbA~1c~ ≤7.7% (135 patients)   HbA~1c~ \>7.7% (30 patients)   *p*-Value
  ----------------------------- ------------------------------ ------------------------------ -----------
  Documented noncompliance                                                                    0.40
   Yes                          35 (25.9%)                     5 (16.7%)                      
   No                           100 (74.1%)                    25 (83.3%)                     
  Failed graft                                                                                0.20
   Yes                          30 (22.2%)                     4 (13.3%)                      
   No                           105 (77.8%)                    26 (86.7%)                     
  Rejection episodes                                                                          0.30
   Yes                          20 (14.8%)                     2 (6.7%)                       
   No                           115 (85.2%)                    28 (93.3%)                     
  Low immunosuppressant level                                                                 0.30
   Yes                          63 (46.7%)                     18 (60.0%)                     
   No                           72 (53.3%)                     12 (40.0%)                     

Data presented as count (percentage).

###### 

Mean HbA~1c~ levels by outcome measure.

                             Mean HbA~1c~   *p*-Value
  -------------------------- -------------- -----------
  Failed graft                              0.40
   Yes                       6.6%           
   No                        6.5%           
  Rejection episodes                        0.80
   Yes                       6.6%           
   No                        6.5%           
  Medication noncompliance                  0.70
   Yes                       6.6%           
   No                        6.4%           

###### 

Comparison of HbA~1c~ levels in CDC data and this study.

               Minimum   25^th^ %ile   Mean   Median   75^th^ %ile   Maximum
  ------------ --------- ------------- ------ -------- ------------- ---------
  CDC data     3.9       6.0           7.2    6.7      7.8           18.0
  This study   4.5       5.6           6.5    6.3      7.2           11.5
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